Advances in the production of human monoclonal antibodies

Abstract

Since the development of hybridoma technology over three decades ago, numerous monoclonal antibodies have been produced and the use of monoclonal antibodies has become one of the major breakthroughs in medicine. Significant progress has been made on new technologies for generating human monoclonal antibodies. This review serves as an introduction to the immortalization of antigen-specific human B cell and hybridoma technologies, phage display platform, the use of transgenic mice, and the generation of monoclonal antibodies from single B cells.

Automated pipeline for rapid production and screening of HIV‐specific monoclonal antibodies using pichia pastoris

“…Historically, the screening and production of antibodies has involved the creation of hybridomas or Epstein‐Barr virus (EBV) transformed human B cells, followed by limiting serial dilution to recover antigen‐specific clones (Wang, ). Generating full‐length antibodies using these techniques is not only time‐consuming, but often results in low material yields from the initial clonal stock (Frame and Hu, ).…”

Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets

“…9 An appreciation of the complexity and diversity of antibody responses in the human population and the resulting rarity of broadly protective memory B cell clones led to the development PAPer TyPe rePorT of a number of human antibody cloning technologies. 10,11 Herein, we employed a multiplexed screening process to enable an in-depth characterization of the specificity of naturally occurring antibodies secreted from single memory B cells. Deeming multiplexing a critical component to discovering antiviral antibodies with cross-clade activity, we counteracted the associated rapid drop in hit frequency with high throughput and miniaturized assay technologies.…”

Застосування Імунобіологічних Лікарських Препаратів На Основі Моноклональних Антитіл У Нефрологічній Практиці

“…На современном этапе медицины в связи с развитием новой фазы терапии применение моноклональных антител в лечении заболеваний находится на первом плане [6]. После того как в 2002 г. были применены для лечения первые полностью чело-Vol.…”